J-P. Machiels

1.9k total citations · 1 hit paper
53 papers, 1.2k citations indexed

About

J-P. Machiels is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, J-P. Machiels has authored 53 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 25 papers in Pulmonary and Respiratory Medicine and 14 papers in Otorhinolaryngology. Recurrent topics in J-P. Machiels's work include Head and Neck Cancer Studies (14 papers), Lung Cancer Treatments and Mutations (14 papers) and Cancer Immunotherapy and Biomarkers (10 papers). J-P. Machiels is often cited by papers focused on Head and Neck Cancer Studies (14 papers), Lung Cancer Treatments and Mutations (14 papers) and Cancer Immunotherapy and Biomarkers (10 papers). J-P. Machiels collaborates with scholars based in Belgium, United States and France. J-P. Machiels's co-authors include Joseph Kerger, Lionel Duck, Lisa Licitra, Paolo Bossi, José A. Hardillo, Ana Castro, Anthony T.�C. Chan, J-L. Canon, Stefan Mattheis and Jana Halámková and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

J-P. Machiels

48 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†

2020 240 citations Paolo Bossi, Lisa Licitra et al. Annals of Oncology profile →

Peers

Countries citing papers authored by J-P. Machiels

Since Specialization

Citations

This map shows the geographic impact of J-P. Machiels's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J-P. Machiels with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J-P. Machiels more than expected).

Fields of papers citing papers by J-P. Machiels

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J-P. Machiels. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J-P. Machiels. The network helps show where J-P. Machiels may publish in the future.

Co-authorship network of co-authors of J-P. Machiels

This figure shows the co-authorship network connecting the top 25 collaborators of J-P. Machiels. A scholar is included among the top collaborators of J-P. Machiels based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J-P. Machiels. J-P. Machiels is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tumor-informed ctDNA assay to predict recurrence in locally advanced squamous-cell carcinoma of the head and neck (SCCHN) 2025 ·ESMO Open ·(unknown), George Laliotis, Vasily N. Aushev, (unknown), Charuta C. Palsuledesai, (unknown), Cédric van Marcke, Rachel Galot, Min Liu, J-P. Machiels	3
2	647P EphA2-targeting bicycle toxin conjugate (BTC) BT5528 in patients (pts) with advanced solid tumors: A phase I/II study 2024 ·Annals of Oncology ·Emily Fontana, (unknown), Meredith McKean, Raid Aljumaily, J-P. Machiels, (unknown), María Vieito, (unknown), Hans Prenen, (unknown), Alastair Greystoke, (unknown), (unknown), Xiaowei Gu, Min Li, Assunta De Rienzo, Babar Bashir	0
3	943TiP Petosemtamab compared with investigator’s choice monotherapy in previously treated patients (pts) with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): A randomized, open-label, phase III trial 2024 ·Annals of Oncology ·(unknown), (unknown), (unknown), S-B. Kim, Christophe Le Tourneau, Allan J. Rosenberg, Jennifer S. Ford, (unknown), (unknown), (unknown), J-P. Machiels	0
4	945TiP JADE: A phase (ph) III study to evaluate dostarlimab vs placebo (PBO) as sequential therapy after chemoradiation (CRT) in patients (pts) with locally advanced unresected head and neck squamous cell carcinoma (LA-HNSCC) 2024 ·Annals of Oncology ·J-P. Machiels, Barbara Burtness, Kevin J. Harrington, Nabil F. Saba, (unknown), (unknown), Hua Li, (unknown), (unknown), (unknown), (unknown)	1
5	854O INTERLINK-1: Phase III study of cetuximab (CTX) ± monalizumab (M) in participants (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on/after platinum chemotherapy (CT) and previously treated with an immune checkpoint inhibitor (ICI) 2023 ·Annals of Oncology ·Jérôme Fayette, Lisa Licitra, Kevin J. Harrington, Robert I. Haddad, Lillian L. Siu, Yi‐Chun Liu, Makoto Tahara, J-P. Machiels, Danny Rischin, Tanguy Y. Seiwert, Robert L. Ferris, Ulrich Keilholz, Amanda Psyrri, Bhumsuk Keam, Paolo Bossi, Robert Metcalf, Oscar K. Serrano, Paramjit Kaur, (unknown), Roger B. Cohen	23
6	92MO Sotorasib (Soto) + panitumumab (Pmab) and FOLFIRI in previously treated KRASG12C-mutated metastatic colorectal cancer (mCRC): Safety and efficacy for CodeBreaK 101 phase Ib expansion cohort 2023 ·Annals of Oncology ·(unknown), (unknown), J-P. Machiels, David S. Hong, Richard Greil, Emily Chan, (unknown), (unknown), (unknown), (unknown), Yasutoshi Kuboki	2
7	Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck 2023 ·Annals of Oncology ·(unknown), Cédric van Marcke, Rachel Galot, Raphaël Helaers, Jérôme Ambroise, Aline van Maanen, Antonella Mendola, (unknown), Étienne Marbaix, P. Van Eeckhout, E. Longton, Michèle Magremanne, Sandra Schmitz, Nisha Limaye, J-P. Machiels	22
8	858O Minimal residual disease (MRD) diagnosed by a plasma tumor-agnostic circulating tumor DNA (ctDNA) assay after curative therapy in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN) predicts disease relapse and survival 2023 ·Annals of Oncology ·(unknown), Cédric van Marcke, Rachel Galot, Raphaël Helaers, Aline van Maanen, Jérôme Ambroise, Antonella Mendola, (unknown), Étienne Marbaix, P. Van Eeckhout, E. Longton, Michèle Magremanne, Sandra Schmitz, Nisha Limaye, J-P. Machiels	1
9	580P TALAPRO-1: Talazoparib (TALA) monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm) - Exploration of non-DDR mutational landscape and potential associations with antitumor activity 2021 ·Annals of Oncology ·(unknown), Johann S. de Bono, Alexander Laird, Philippe Barthélémy, R. Delva, Tanya B. Dorff, Marco Maruzzo, A. Stirling, J-P. Machiels, Herlinde Dumez, Vincent Renard, Julia F. Hopkins, Lee A. Albacker, Hsiang‐Cheng Chen, Cynthia G. Healy, Jijumon Chelliserry, Inge M. van Oort, Giorgio V. Scagliotti, Karim Fizazi	1
10	973TiP LEAP-010: Phase III study of first-line pembrolizumab with or without lenvatinib in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) 2020 ·Annals of Oncology ·Lillian L. Siu, Barbara Burtness, (unknown), Kevin J. Harrington, Lisa Licitra, Danny Rischin, Ying Zhu, Chinyere E. Okpara, (unknown), Ramona F. Swaby, J-P. Machiels, Makoto Tahara	1
11	Phase 3 KEYNOTE-412 trial: Pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) 2017 ·Annals of Oncology ·J-P. Machiels, C-J. Yen, Lisa Licitra, Danny Rischin, John Waldron, Barbara Burtness, V. Grégoire, Yungan Tao, Jeffrey T. Yorio, Sercan Aksoy, Sadakatsu Ikeda, (unknown), Joy Yang Ge, Holly Brown, Behzad Bidadi, Lillian L. Siu	0
12	Phase I study of ribociclib plus cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck 2016 ·Annals of Oncology ·Emmanuel Seront, Sandra Schmitz, Sylvie Rottey, Stéphanie Henry, Christophe Lonchay, (unknown), (unknown), J-P. Machiels	3
13	343TiP Pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer: Methodology of phase 3 randomized trial 2015 ·Annals of Oncology ·J-P. Machiels, (unknown), Ezra E.W. Cohen, Kevin J. Harrington, Barbara Burtness, Christine K. Gause, A. Swift, Ramona F. Swaby, Christophe Le Tourneau	1
14	Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study 2015 ·Annals of Oncology ·J. Guigay, Jérôme Fayette, Anne-Françoise Dillies, Clément Sire, Joseph Kerger, Isabelle Tennevet, J-P. Machiels, Sylvie Zanetta, Y. Pointreau, L. Bozec Le Moal, Stéphanie Henry, A. Schilf, Jean Bourhis	100
15	A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors 2013 ·Annals of Oncology ·Jan B. Vermorken, Sylvie Rottey, E. Ehrnrooth, (unknown), (unknown), Sven Wind, J-P. Machiels	31
16	Epidermal growth factor receptor targeted therapies for solid tumours. 2011 ·DIAL (Catholic University of Leuven) ·Marc Van den Eynde, J.F. Baurain, Filomena Mazzeo, J-P. Machiels	30
17	Cancer and renal insufficiency results of the BIRMA study 2010 ·British Journal of Cancer ·Nicolas Janus, Vincent Launay‐Vacher, (unknown), J-P. Machiels, Lionel Duck, Joseph Kerger, Wim Wynendaele, J-L. Canon, Willem Lybaert, Joëlle Nortier, (unknown), Hans Wildiers	133
18	TRASTUZUMAB TREATMENT OF EARLY STAGE BREAST CANCER IS COST-EFFECTIVE FROM THE PERSPECTIVE OF THE BELGIAN HEALTH CARE AUTHORITIES 2009 ·Acta Clinica Belgica ·Ilse Van Vlaenderen, J.-L. Canon, V. Cocquyt, Guy Jérusalem, J-P. Machiels, Patrick Neven, (unknown), (unknown), Marlene Gyldmark, Lieven Annemans	19
19	Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer 2007 ·Annals of Oncology ·J-P. Machiels, Christine Sempoux, Pierre Scalliet, J.-C. Coche, Yves Humblet, Eric Van Cutsem, Joseph Kerger, J-L. Canon, Marc Peeters, Selda Aydın, Stéphanie Laurent, Alex Kartheuser, B. Coster, Sarah Roels, Jean‐François Daisne, Brigitte Honhon, Lionel Duck, Carine Kirkove, (unknown), Karin Haustermans	118
20	Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study 2005 ·Annals of Oncology ·J-P. Machiels, Lionel Duck, Brigitte Honhon, B. Coster, J.-C. Coche, Pierre Scalliet, Yves Humblet, Selda Aydın, Joseph Kerger, Vincent Remouchamps, J.-L. Canon, (unknown), L. Gilbeau, Stéphanie Laurent, (unknown), M. Octave-Prignot, Jean‐François Baurain, (unknown), Christine Sempoux	106

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact